26.08.2025

According to the ECDC report, from the beginning of 2025 until July, approximately 240,000 cases of Chikungunya and about 90 deaths were recorded across 16 countries and territories.
Chikungunya is a viral disease caused by the Chikungunya virus (CHIKV), a member of the Togaviridae family, genus Alphavirus. The virus is transmitted to humans through bites of Aedes mosquitoes. These mosquitoes are daytime feeders, which increases the risk of transmission.
Two vaccines against the disease are currently available:
Ixchiq: a live-attenuated vaccine, produced by Valneva Austria GmbH (a French company).
Vimkunya: a virus-like particle (VLP) vaccine, produced by Bavarian Nordic.

The Ixchiq vaccine was approved by the FDA in November 2023 for use in adults aged 18 years and older at increased risk of exposure to the virus. The EMA (European Medicines Agency) also granted approval in June 2024. In May 2025, the FDA and CDC announced the suspension of its use in individuals aged 65 years and older, following reports of severe adverse events, including serious cardiovascular complications. Initially, its use was temporarily suspended, but in June–July 2025, the FDA and EMA lowered the age restriction and allowed continued administration only to individuals not considered at-risk.
Most recently, the FDA announced the full and immediate suspension of the vaccine’s licensure in the United States, following four additional severe adverse events.
In the first half of the year, Ixchiq recorded sales of €7.5 million (approximately $8.8 million).